Margaretta Colangelo

Margaretta Colangelo is Co-founder and CEO of Jthereum an enterprise Blockchain company and President of U1 Technologies an enterprise software company. She has published over 300 articles on AI and DeepTech. Margaretta serves on the advisory board of the AI Precision Health Institute at the University of Hawaii Cancer Center. She is based in San Francisco.

 

10 Highlights From The 2022 Artificial Intelligence Index Report

The 5th edition of the Artificial Intelligence Index Report entitled Measuring Trends in Artificial Intelligence was released this week. The report, produced by the Stanford Institute for Human-Centered Artificial Intelligence (HAI), is one of the most credible sources for data about AI worldwide. This year’s report is 299 pages long and includes 173 visualizations. The report also […]

10 Highlights From The 2022 Artificial Intelligence Index Report Read More »

Deepcell Raises $73 Million to Advance AI Powered Single Cell Analysis

“AI can learn to identify cells based on visual differences that are hardly accessible to the human eye and can continually improve, thanks to our capability to sort cells and thereby elicit ground truth at scale. With training on billions of cell images and sorting cells, our AI technology connects morphology to multiomics, delivering unprecedented

Deepcell Raises $73 Million to Advance AI Powered Single Cell Analysis Read More »

PathAI and Cleveland Clinic Announce 5 Year Strategic Collaboration

“Our commitment is to provide the best possible care for our patients, and it is increasingly clear that AI-powered pathology can radically enhance diagnostic accuracy and treatment selection.” Dr. Brian Rubin, chair of Pathology and Laboratory Medicine Institute, Cleveland Clinic PathAI and Cleveland Clinic have announced a 5 year strategic collaboration. The partnership will combine

PathAI and Cleveland Clinic Announce 5 Year Strategic Collaboration Read More »

National Heart Centre Singapore Launches AI Lab for Cardiac Imaging

“We are excited to spearhead research on the use of AI in the clinical setting. AI can potentially capture and make sense of complex image information in a multidimensional manner, improve predictive ability, and reduce labor and time intensive processes.” Assistant Professor Lohendran Baskaran, Clinical Lead, Cardiovascular Systems Imaging and AI Lab, NHCS On March

National Heart Centre Singapore Launches AI Lab for Cardiac Imaging Read More »

Stanford Researchers Use AI To Sequence and Analyze DNA In 5 hours

“A few weeks is what most clinicians call ‘rapid’ when it comes to sequencing a patient’s genome and returning results.”  Dr. Euan Ashley, professor of medicine, genetics and biomedical data science, Stanford School of Medicine In a new milestone, Dr. Euan Ashley and his colleagues Stanford School of Medicine used AI to sequence and analyze

Stanford Researchers Use AI To Sequence and Analyze DNA In 5 hours Read More »

Highlights From The Riyadh Global Summit for Artificial Intelligence In Healthcare

This weekend the Riyadh Global Summit for Artificial Intelligence In Healthcare took place in The Kingdom of Saudi Arabia. Leading AI scientists, Pharma executives, and business leaders from around the world came together to explore the potential of AI, machine learning, and deep learning in healthcare. Distinguished speakers attended from The Kingdom of Saudi Arabia,

Highlights From The Riyadh Global Summit for Artificial Intelligence In Healthcare Read More »

FDA Approves AI That Helps Hospitals Reduce Missed Fractures By 29%

This week the FDA approved Gleamer BoneView® AI software to detect fractures and traumatic skeletal injuries in the US. This is the first solution to receive FDA and CE clearance in this category. In a recent study BoneView helped hospitals reduce missed fractures by 29% and increased sensitivity by 30% for exams with more than one fracture. In the

FDA Approves AI That Helps Hospitals Reduce Missed Fractures By 29% Read More »

Major Milestone Reached: First AI-Developed Drug Enters Phase 1 Trial

“It gives me great pleasure to announce that we have completed our first human in Phase 0 clinical trial and entered the full Phase 1 clinical trial with a once-a-day oral dose of our ISM001-055 anti-fibrotic where the target was identified using AI and the molecule was designed using AI, meaning it is AI-discovered and AI-designed.“

Major Milestone Reached: First AI-Developed Drug Enters Phase 1 Trial Read More »

AI Identifies Live Cancer Cells In Less Than 35 Minutes With 95% Accuracy

Researchers at National University of Singapore have developed a novel protocol using AI and inexpensive equipment to identify live cancer cells in less than 35 minutes with 95% accuracy. The ability to analyze single cells is one of the holy grails of precision medicine. Yuri Belotti, PhD, Doorgesh Sharma Jokhun, PhD, and Professor Chwee Teck (C.T.) Lim at

AI Identifies Live Cancer Cells In Less Than 35 Minutes With 95% Accuracy Read More »

AI In Healthcare Highlights & Milestones 2021

AI in Healthcare companies are making significant progress. We’ve reached the threshold of a new era where advanced technologies will improve the way we understand, treat, and prevent disease. In 2021 the application of AI enabled advances in many areas of healthcare. We made significant progress in AI for drug discovery, medical imaging, diagnostics, pathology,

AI In Healthcare Highlights & Milestones 2021 Read More »

Scroll to Top